Developer docs
API playgroundTry for free, no card

Search company profiles

SERVIER LABORATORIES

Full company profile

uuid00vq4nj

Namestring
SERVIER LABORATORIES
Legal namestring
Công Ty TNHH Servier (Việt Nam)
Websiteurl
servier.vn
Company typeenum
Private
Founded yearint
1993
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHo Chi Minh City, Vietnam
HQ citystring
Ho Chi Minh City
HQ countrystring
Vietnam
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical products, cardiovascular medicine, oncology therapeutics, diabetes treatments, venous disease therapies
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Products
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Servier generates revenue primarily through the sale of prescription pharmaceutical products across its therapeutic areas: cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases (chronic venous disease, hemorrhoids), immune-inflammatory diseases, and neuroscience. Servier is a non-profit foundation-governed company that reinvests all net revenue into R&D.

servier.vn
2Technology Transfer and Manufacturing
TypeLicensing Royalties
Description

Servier generates revenue through technology transfer arrangements with local Vietnamese partners, such as the Ampharco partnership, where local manufacturers produce Servier's originator drugs for the Vietnamese market under licensing and technology transfer agreements.

servier.vn
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MyServier
Description

Exclusive platform for healthcare professionals in Vietnam with in-depth content on therapeutic areas and product information

servier.vn
+2 more records
Core offering1 text field

Servier Laboratories develops, manufactures, and markets prescription pharmaceutical products across cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases, immune-inflammatory diseases, neuroscience, and oncology therapeutic areas in Vietnam. The company also offers digital health solutions including the MyServier HCP platform, the Elfie blood pressure monitoring app, and the Ngày Đầu Tiên early diagnosis program serving over 3 million Vietnamese patients annually.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 3 million Vietnamese patients treated annually with Servier drugs
+5 more records
Product overview1 text field

Servier Laboratories is an independent French pharmaceutical company governed by a non-profit foundation, operating in Vietnam since 1993. Its product portfolio centers on four core therapeutic areas: cardiovascular-metabolic therapies (covering hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases), immune-inflammatory therapies (lupus, scleroderma, Sjögren's syndrome), neuroscience (Parkinson's, autism), and oncology. Servier Vietnam serves over 3 million Vietnamese patients annually and operates several patient-facing digital tools: MyServier (a dedicated platform for healthcare professionals providing clinical content), the Elfie app (supporting patient treatment adherence and blood pressure monitoring), and the Ngày Đầu Tiên (First Day) project (a patient early-diagnosis and disease-management initiative). The company also pursues technology transfer partnerships such as the Ampharco arrangement to manufacture originator products domestically.

Product and service7 records
1MyServier HCP Portal
CategoryDigital Health Platform
Description

A dedicated online platform for healthcare professionals working in Vietnam, providing in-depth clinical content in areas of coronary artery disease, venous disease, diabetes, and hypertension, as well as information on Servier Vietnam's products.

2Elfie Mobile App
CategoryDigital Health Application
Description

A mobile application that helps patients improve treatment adherence, and track and control blood pressure.

3Ngày Đầu Tiên (First Day) Project
CategoryPatient Support Program
Description

A program designed to help patients with hypertension, diabetes, and angina receive early diagnosis and better disease management.

4Cardiovascular-Metabolic Therapies
CategoryPharmaceutical Product
Description

Servier's core therapeutic area covering cardiovascular diseases with fixed-dose combination products (SPC) designed to simplify treatment and improve patient adherence. This includes treatments for hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases.

5Immune-Inflammatory Therapies
CategoryPharmaceutical Product
Description

Servier's therapeutic area focusing on immune-inflammatory diseases with R&D efforts concentrated on three autoimmune conditions with high unmet medical needs: systemic lupus erythematosus, scleroderma, and Sjögren's syndrome.

6Neuroscience Therapies
CategoryPharmaceutical Product
Description

Servier's therapeutic area focusing on neurodegenerative diseases and protein pathologies characterized by abnormal protein accumulation, including Parkinson's disease and rare diseases such as unilateral muscle atrophy sclerosis. Servier is collaborating with Neurochlore on Phase III studies for autism spectrum disorder.

7Oncology Therapies
CategoryPharmaceutical Product
Description

Servier's therapeutic area covering cancer treatment development, representing 25% of global turnover and 70% of R&D investments.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-27
Description

Servier and Ampharco entered a technology transfer agreement for the local production of Servier's originator drugs in Vietnam. The partnership began in 2019, with Ampharco's plant completed in 2022 and EU-GMP certification achieved in 2025. When fully deployed, Ampharco will produce half of Servier's total originator drug volume for Vietnam. The agreement was signed at the French Embassy in Hanoi on May 27, 2025, witnessed by the French Minister of Economy and Vietnamese government officials. This aligns with Vietnam's goal to produce 100 originators domestically and 80% of medicines locally by 2045.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-08
Description

Servier Vietnam partners with Youmed (Công Ty TNHH YouMed Việt Nam) as a data controller for the NDT Nurse Program. Youmed provides the Y360 online learning platform for the program, manages user accounts for nurse participants, and delivers program communications. This program provides CME-certified training for nurses in Vietnam.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-08
Description

Hanoi Medical University collaborates with Servier Vietnam as a data controller for the NDT Nurse Program, providing Zoom-based online training sessions and CME certification for participating nurses. This partnership supports advanced nursing education and professional development in Vietnam.

4Bảo Yên District Communities (Lào Cai Province)
Strategic tierMinorTypeOthersAnnounced on2024-11-24
Description

Servier Vietnam's 'Nowadays' team organized the 'Hướng về Bảo Yên thân thương' program, delivering disaster relief to communities affected by Typhoon Yagi in Lào Cai province. The company donated nearly 3 tons of rice and essential supplies to over 90 households and organized tree planting for environmental recovery in Xuân Thượng and Xuân Hòa communes.

servier.vn
Strategic tierMinorTypeOthersAnnounced on2019-01-01
Description

Since September 2019, Servier Vietnam has partnered with Enfants d'Asie on three programs: supporting highland youth studying at universities in HCMC, partnering with the HCMC Women's Charity Association (WOCA) to support 50 underprivileged students in primary and secondary school, and collaborating with Maison d'Amour religious congregation to support 90 children in suburban HCMC.

Strategic tierMinorTypeOthersAnnounced on2019-01-01
Description

Since January 2019, Grow Green is an environmental initiative by Servier Vietnam with the mission of changing perceptions about environmental challenges, raising awareness about plastic pollution, and providing tools for behavioral change with a positive impact on the environment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Servier Vietnam participates in the ChildSight program, a vision screening and treatment initiative for children and teachers in underserved provinces of Vietnam, in partnership with Helen Keller International and Helen Keller Vietnam.

Strategic tierMinorTypeOthersAnnounced on2017-01-01
Description

From April 2017 to June 2020, Servier Vietnam supported LP4Y, a program helping disadvantaged Vietnamese youth aged 17–24 who had dropped out of school, by sharing knowledge, skills, and practical experience to help them approach their dreams and improve their employment prospects.

9Vietnam Cardiology Society (Hội Tim mạch học Việt Nam)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

The Vietnam Cardiology Society co-sponsors the 'Ngày Đầu Tiên' (First Day) project, an early diagnosis and disease management initiative for hypertension, diabetes, and angina patients. This project has been operating since 2015 and is officially recognized by the Ministry of Health of Vietnam.

servier.vn
10Vietnam Diabetes & Endocrinology Association (Hội Nội tiết & Đái tháo đường Việt Nam)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

The Vietnam Diabetes & Endocrinology Association co-sponsors the 'Ngày Đầu Tiên' (First Day) project alongside the Vietnam Cardiology Society and Servier Vietnam, contributing to early diagnosis and better disease control for diabetes and hypertension patients in Vietnam since 2015.

servier.vn
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global pharmaceutical leader with a dominant oncology portfolio entering Vietnam; competes with Servier's expanding oncology ambitions and shares the multinational HCP engagement model.

TypeRegional player
Description

One of the largest domestic Vietnamese pharmaceutical manufacturers; competes with Servier in cardiovascular and diabetes generics and is a likely local partner/competitor in the government's drive for domestic originator production.

TypeDirect peer
Description

Multinational pharmaceutical company with strong diabetes, oncology, and vaccine franchises in Vietnam; competes with Servier in cardio-metabolic care and shares a similar multinational HCP-engagement playbook.

TypeDirect peer
Description

French-headquartered multinational pharmaceutical company with a strong Vietnam presence across cardiovascular, diabetes, and specialty therapeutics; competes directly with Servier Vietnam for HCP relationships and chronic-disease market share.

TypeDirect peer
Description

German multinational with a significant cardiovascular and cardiometabolic portfolio in Vietnam; directly overlaps with Servier's hypertension and chronic-disease therapeutic focus.

TypeDirect peer
Description

Japanese-headquartered multinational with a presence across specialty, oncology, and rare disease therapeutics in Vietnam; competes for HCP mindshare and specialty-pharma positioning alongside Servier.

TypeDirect peer
Description

Global biopharmaceutical company with major cardiovascular and oncology franchises in Vietnam; competes with Servier in cardiology and increasingly in oncology where Servier is reallocating R&D.

TypeDirect peer
Description

Swiss-headquartered multinational with strong cardiovascular and specialty care presence in Vietnam; competes with Servier in hypertension, heart failure, and chronic disease management.

TypeDirect peer
Description

One of the largest multinational pharmaceutical companies in Vietnam with broad cardiovascular, oncology, and specialty portfolios; competes for the same top-10 MNC ranking and HCP access that Servier holds.

10Boehringer Ingelheim Vietnam
TypeDirect peer
Description

Germany-based multinational with a leading cardiometabolic and respiratory franchise, including diabetes and stroke prevention; closely competes with Servier's diabetes and cardiovascular offerings in Vietnam.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SERVIER LABORATORIES

Pharmaceutical Productsservier.vn

SERVIER LABORATORIES firmographics

Firmographics
Name
SERVIER LABORATORIES
Legal name
Công Ty TNHH Servier (Việt Nam)
Website
https://servier.vn
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

SERVIER LABORATORIES industry classification

Industry
Product category
Pharmaceutical Products
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical products
  • Cardiovascular medicine
  • Oncology therapeutics
  • Diabetes treatments
  • Venous disease therapies

Where SERVIER LABORATORIES is headquartered

Location

Headquarters

HQ city
Ho Chi Minh City
HQ country
Vietnam
HQ region
Asia

Offices1 record

Markets served

SERVIER LABORATORIES business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Servier generates revenue primarily through the sale of prescription pharmaceutical products across its therapeutic areas: cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases (chronic venous disease, hemorrhoids), immune-inflammatory diseases, and neuroscience. Servier is a non-profit foundation-governed company that reinvests all net revenue into R&D.
  2. Technology Transfer and Manufacturing: Servier generates revenue through technology transfer arrangements with local Vietnamese partners, such as the Ampharco partnership, where local manufacturers produce Servier's originator drugs for the Vietnamese market under licensing and technology transfer agreements.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

SERVIER LABORATORIES product offering

Product offering

Core offering

Servier Laboratories develops, manufactures, and markets prescription pharmaceutical products across cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases, immune-inflammatory diseases, neuroscience, and oncology therapeutic areas in Vietnam. The company also offers digital health solutions including the MyServier HCP platform, the Elfie blood pressure monitoring app, and the Ngày Đầu Tiên early diagnosis program serving over 3 million Vietnamese patients annually.

Product overview

Servier Laboratories is an independent French pharmaceutical company governed by a non-profit foundation, operating in Vietnam since 1993. Its product portfolio centers on four core therapeutic areas: cardiovascular-metabolic therapies (covering hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases), immune-inflammatory therapies (lupus, scleroderma, Sjögren's syndrome), neuroscience (Parkinson's, autism), and oncology. Servier Vietnam serves over 3 million Vietnamese patients annually and operates several patient-facing digital tools: MyServier (a dedicated platform for healthcare professionals providing clinical content), the Elfie app (supporting patient treatment adherence and blood pressure monitoring), and the Ngày Đầu Tiên (First Day) project (a patient early-diagnosis and disease-management initiative). The company also pursues technology transfer partnerships such as the Ampharco arrangement to manufacture originator products domestically.

Differentiator

Problem solved

Functional benefit

Brands

  • MyServier: Exclusive platform for healthcare professionals in Vietnam with in-depth content on therapeutic areas and product information
  • Elfie
  • Ngày Đầu Tiên (First Day)

Products and services

  • MyServier HCP Portal A dedicated online platform for healthcare professionals working in Vietnam, providing in-depth clinical content in areas of coronary artery disease, venous disease, diabetes, and hypertension, as well as information on Servier Vietnam's products.
  • Elfie Mobile App A mobile application that helps patients improve treatment adherence, and track and control blood pressure.
  • Ngày Đầu Tiên (First Day) Project A program designed to help patients with hypertension, diabetes, and angina receive early diagnosis and better disease management.
  • Cardiovascular-Metabolic Therapies Servier's core therapeutic area covering cardiovascular diseases with fixed-dose combination products (SPC) designed to simplify treatment and improve patient adherence. This includes treatments for hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases.
  • Immune-Inflammatory Therapies Servier's therapeutic area focusing on immune-inflammatory diseases with R&D efforts concentrated on three autoimmune conditions with high unmet medical needs: systemic lupus erythematosus, scleroderma, and Sjögren's syndrome.
  • Neuroscience Therapies Servier's therapeutic area focusing on neurodegenerative diseases and protein pathologies characterized by abnormal protein accumulation, including Parkinson's disease and rare diseases such as unilateral muscle atrophy sclerosis. Servier is collaborating with Neurochlore on Phase III studies for autism spectrum disorder.
  • Oncology Therapies Servier's therapeutic area covering cancer treatment development, representing 25% of global turnover and 70% of R&D investments.

Quantifiable outcome

  • Over 3 million Vietnamese patients treated annually with Servier drugs
  • +5 more outcomes

Companies that use SERVIER LABORATORIES

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

SERVIER LABORATORIES technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SERVIER LABORATORIES partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

  • AmpharcoflagshipStrategic or Co-development Partner · 27 May 2025Servier and Ampharco entered a technology transfer agreement for the local production of Servier's originator drugs in Vietnam. The partnership began in 2019, with Ampharco's plant completed in 2022 and EU-GMP certification achieved in 2025. When fully deployed, Ampharco will produce half of Servier's total originator drug volume for Vietnam. The agreement was signed at the French Embassy in Hanoi on May 27, 2025, witnessed by the French Minister of Economy and Vietnamese government officials. This aligns with Vietnam's goal to produce 100 originators domestically and 80% of medicines locally by 2045.
  • Youmed VietnamcoreStrategic or Co-development Partner · 8 April 2025Servier Vietnam partners with Youmed (Công Ty TNHH YouMed Việt Nam) as a data controller for the NDT Nurse Program. Youmed provides the Y360 online learning platform for the program, manages user accounts for nurse participants, and delivers program communications. This program provides CME-certified training for nurses in Vietnam.
  • Hanoi Medical University (Đại học Y Hà Nội)coreStrategic or Co-development Partner · 8 April 2025Hanoi Medical University collaborates with Servier Vietnam as a data controller for the NDT Nurse Program, providing Zoom-based online training sessions and CME certification for participating nurses. This partnership supports advanced nursing education and professional development in Vietnam.
  • Bảo Yên District Communities (Lào Cai Province)minorOthers · 24 November 2024Servier Vietnam's 'Nowadays' team organized the 'Hướng về Bảo Yên thân thương' program, delivering disaster relief to communities affected by Typhoon Yagi in Lào Cai province. The company donated nearly 3 tons of rice and essential supplies to over 90 households and organized tree planting for environmental recovery in Xuân Thượng and Xuân Hòa communes.
  • Enfants d'AsieminorOthers · 1 January 2019Since September 2019, Servier Vietnam has partnered with Enfants d'Asie on three programs: supporting highland youth studying at universities in HCMC, partnering with the HCMC Women's Charity Association (WOCA) to support 50 underprivileged students in primary and secondary school, and collaborating with Maison d'Amour religious congregation to support 90 children in suburban HCMC.
  • Grow GreenminorOthers · 1 January 2019Since January 2019, Grow Green is an environmental initiative by Servier Vietnam with the mission of changing perceptions about environmental challenges, raising awareness about plastic pollution, and providing tools for behavioral change with a positive impact on the environment.
  • Helen Keller International / Helen Keller VietnamminorStrategic or Co-development Partner · 1 January 2018Servier Vietnam participates in the ChildSight program, a vision screening and treatment initiative for children and teachers in underserved provinces of Vietnam, in partnership with Helen Keller International and Helen Keller Vietnam.
  • LP4Y (Life Project 4 Youth)minorOthers · 1 January 2017From April 2017 to June 2020, Servier Vietnam supported LP4Y, a program helping disadvantaged Vietnamese youth aged 17–24 who had dropped out of school, by sharing knowledge, skills, and practical experience to help them approach their dreams and improve their employment prospects.
  • Vietnam Cardiology Society (Hội Tim mạch học Việt Nam)coreStrategic or Co-development Partner · 1 January 2015The Vietnam Cardiology Society co-sponsors the 'Ngày Đầu Tiên' (First Day) project, an early diagnosis and disease management initiative for hypertension, diabetes, and angina patients. This project has been operating since 2015 and is officially recognized by the Ministry of Health of Vietnam.
  • Vietnam Diabetes & Endocrinology Association (Hội Nội tiết & Đái tháo đường Việt Nam)coreStrategic or Co-development Partner · 1 January 2015The Vietnam Diabetes & Endocrinology Association co-sponsors the 'Ngày Đầu Tiên' (First Day) project alongside the Vietnam Cardiology Society and Servier Vietnam, contributing to early diagnosis and better disease control for diabetes and hypertension patients in Vietnam since 2015.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

SERVIER LABORATORIES competitors and assessment

Company assessment

Direct peers

  • Roche Vietnam: Global pharmaceutical leader with a dominant oncology portfolio entering Vietnam; competes with Servier's expanding oncology ambitions and shares the multinational HCP engagement model.
  • MSD (Merck) Vietnam: Multinational pharmaceutical company with strong diabetes, oncology, and vaccine franchises in Vietnam; competes with Servier in cardio-metabolic care and shares a similar multinational HCP-engagement playbook.
  • Sanofi Vietnam: French-headquartered multinational pharmaceutical company with a strong Vietnam presence across cardiovascular, diabetes, and specialty therapeutics; competes directly with Servier Vietnam for HCP relationships and chronic-disease market share.
  • Bayer Vietnam: German multinational with a significant cardiovascular and cardiometabolic portfolio in Vietnam; directly overlaps with Servier's hypertension and chronic-disease therapeutic focus.
  • Takeda Pharmaceuticals Vietnam: Japanese-headquartered multinational with a presence across specialty, oncology, and rare disease therapeutics in Vietnam; competes for HCP mindshare and specialty-pharma positioning alongside Servier.
  • AstraZeneca Vietnam: Global biopharmaceutical company with major cardiovascular and oncology franchises in Vietnam; competes with Servier in cardiology and increasingly in oncology where Servier is reallocating R&D.
  • Novartis Vietnam: Swiss-headquartered multinational with strong cardiovascular and specialty care presence in Vietnam; competes with Servier in hypertension, heart failure, and chronic disease management.
  • Pfizer Vietnam: One of the largest multinational pharmaceutical companies in Vietnam with broad cardiovascular, oncology, and specialty portfolios; competes for the same top-10 MNC ranking and HCP access that Servier holds.
  • Boehringer Ingelheim Vietnam: Germany-based multinational with a leading cardiometabolic and respiratory franchise, including diabetes and stroke prevention; closely competes with Servier's diabetes and cardiovascular offerings in Vietnam.

Regional players

  • DHG Pharmaceutical Joint Stock Company: One of the largest domestic Vietnamese pharmaceutical manufacturers; competes with Servier in cardiovascular and diabetes generics and is a likely local partner/competitor in the government's drive for domestic originator production.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

SERVIER LABORATORIES social profiles

Digital presence

SERVIER LABORATORIES compliance and trust

Trust signal

Compliance1 record

SERVIER LABORATORIES financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SERVIER LABORATORIES leadership team

Management profile

Number of profiles

Profiles2 records

SERVIER LABORATORIES subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SERVIER LABORATORIES funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SERVIER LABORATORIES M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SERVIER LABORATORIES

What does SERVIER LABORATORIES do?

Servier Laboratories develops, manufactures, and markets prescription pharmaceutical products across cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases, immune-inflammatory diseases, neuroscience, and oncology therapeutic areas in Vietnam. The company also offers digital health solutions including the MyServier HCP platform, the Elfie blood pressure monitoring app, and the Ngày Đầu Tiên early diagnosis program serving over 3 million Vietnamese patients annually.

Is SERVIER LABORATORIES a public or private company?

SERVIER LABORATORIES is a private company. It is classified as corporate owned and is currently operating.

When was SERVIER LABORATORIES founded?

SERVIER LABORATORIES was founded in 1993. It employs 101 to 250 people.

Where is SERVIER LABORATORIES based?

SERVIER LABORATORIES is headquartered in Ho Chi Minh City, Vietnam, in the Asia region.

How does SERVIER LABORATORIES make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are technology Transfer and Manufacturing.

Who are SERVIER LABORATORIES's main competitors?

Direct peers on record are Roche Vietnam, MSD (Merck) Vietnam, Sanofi Vietnam, Bayer Vietnam, Takeda Pharmaceuticals Vietnam, AstraZeneca Vietnam, Novartis Vietnam, Pfizer Vietnam and Boehringer Ingelheim Vietnam. DHG Pharmaceutical Joint Stock Company is listed as a regional player.

Does SERVIER LABORATORIES have an API?

No public API is recorded for SERVIER LABORATORIES.

What industry is SERVIER LABORATORIES in?

SERVIER LABORATORIES's product category is Pharmaceutical Products. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales